![Bendamustin–Rituximab Combination Is a Safe and Effective, Ambulatory Treatment for Elderly Patients with Chronic Lymphocytic Leukemia: Retrospective Real-world Analysis by Age from a German Registry and Review of the Literature | Anticancer Bendamustin–Rituximab Combination Is a Safe and Effective, Ambulatory Treatment for Elderly Patients with Chronic Lymphocytic Leukemia: Retrospective Real-world Analysis by Age from a German Registry and Review of the Literature | Anticancer](https://ar.iiarjournals.org/content/anticanres/36/6/2827/F13.large.jpg)
Bendamustin–Rituximab Combination Is a Safe and Effective, Ambulatory Treatment for Elderly Patients with Chronic Lymphocytic Leukemia: Retrospective Real-world Analysis by Age from a German Registry and Review of the Literature | Anticancer
![Intas Bendamustine (100mg) INJECTION, Dosage Form: Liquid, Packaging: Vial at Rs 3500/pack in Nagpur Intas Bendamustine (100mg) INJECTION, Dosage Form: Liquid, Packaging: Vial at Rs 3500/pack in Nagpur](https://5.imimg.com/data5/SELLER/Default/2020/11/QC/HG/HL/34366115/bendamustine-100mg-injection-1000x1000.jpg)
Intas Bendamustine (100mg) INJECTION, Dosage Form: Liquid, Packaging: Vial at Rs 3500/pack in Nagpur
Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi | Haematologica
![Table 4 from Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial | Semantic Scholar Table 4 from Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/c6a451dc67118286212b983f6ac891561aa0279d/6-Table4-1.png)
Table 4 from Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial | Semantic Scholar
![Bendamustine treatment of Chinese patients with relapsed indolent non-Hodgkin lymphoma: a multicenter, open-label, single-arm, phase 3 study | Chinese Medical Journal Bendamustine treatment of Chinese patients with relapsed indolent non-Hodgkin lymphoma: a multicenter, open-label, single-arm, phase 3 study | Chinese Medical Journal](https://mednexus.org/cms/10.1097/CM9.0000000000001463/asset/fa4bbf3c-a55e-4696-a60c-68b367dbb411/assets/graphic/0366-6999-134-11-007-f002.png)
Bendamustine treatment of Chinese patients with relapsed indolent non-Hodgkin lymphoma: a multicenter, open-label, single-arm, phase 3 study | Chinese Medical Journal
![Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial - The Lancet Oncology Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/asset/3bb8ddcc-a8bf-4b08-836c-aa35237380a7/gr1.gif)